All In Biotech

Drug Trial Radar · NCT00578786

A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)

Last checked: Nov 20, 2026Latest source record: Jan 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 383 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

383

Actual

Start

Feb 2004

Primary completion

Mar 2010

Study completion Mar 2010

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Dec 21, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AMB-320/321-E was designed to provide long-term, controlled monitoring of pulmonary arterial hypertension (PAH) patients treated with ambrisentan (AMB) in order to properly define the adverse event profile associated with this endothelin receptor antagonist (ERA), including the incidence and severity of elevated serum liver function tests (LFTs). In addition, this study continued the efficacy assessments of the previous studies, examined long-term AMB treatment success, and compared long-term survival of subjects treated with AMB to the NIH registry of patients with PAH.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • ambrisentanDrug

    2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequently Reported (15% or More Overall) Adverse Events by SeverityTime frame: Baseline to Week 295
  2. Serum Aminotransferases Relative to the Upper Limit of the Normal Range (ULN)Time frame: Baseline to Week 295

Locations

22 sites in 4 countries. Site status is shown where the registry gives one.

  • Hospital Privado Centro Medico de Cordoba

    Córdoba, Argentina

  • Sanatorio Otamendi

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Hospital Britanico-Buenos Aires

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Instituto del Corazon Denton A. Cooley

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • UAI Hosp. Universitario

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • HIGA Hospital Interzonal General de Agudos Oscar Allende

    Mar del Plata, Buenos Aires, Argentina

  • Clinica Independencia Munro

    Munro, Buenos Aires, Argentina

  • Sanatorio Allende

    Córdoba, Córdoba Province, Argentina

  • Hospital Italiano de Cordoba

    Córdoba, Córdoba Province, Argentina

  • Instituto de Cardiologia J.F. Cabral

    Corrientes, Corrientes Province, Argentina

  • Hospital Italiano de Rosario

    Rosario, Sante Fe, Argentina

  • Hospital Madre Teresa

    Belo Horizonte, Brazil

  • Hospital San Lucas de Pontificia Universidade Catolica

    Porto Alegre, Brazil

  • Complexo Hospitalar Sanata Casa de Porto Alegre

    Porto Alegre, Brazil

  • Universidade do Estado de Sao Paulo - UNIFESP

    São Paulo, Brazil

  • Hospital das Clinicas da FMUSP

    São Paulo, Brazil

  • Hospital Universitario Clementino Fraga Filho

    Ilha Do Fundao, Rio de Janeiro, Brazil

  • Hospital San Juan de Dios

    Santiago, Santiago de Chile, Chile

  • Hospital Clinico Universidad Catolica

    Santiago, Santiago de Chile, Chile

  • Instituto Nacional del Torax

    Santiago, Santiago de Chile, Chile

  • Instituto Nacional de Cardiologia Ignacio Chavez

    Mexico City, Mexico City, Mexico

  • Unidad De Investigacion Clinica en Medicina

    Monterrey, Nuevo Leon, Nuevo León, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.